Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C.

摘要: Background/Aims Chronic Hepatitis C virus (HCV) infection is common and often produces a progressive disease. Some studies suggest that HCV related complications will increase in the future. Our aim was to estimate future morbidity, mortality costs of chronic cohort patients infected by evaluate impact therapy. Methods A mathematical model used project over next 30 years, 419,895 representing population Spain. The therapy with peginterferon ribavirin this also projected. Results gradual decline expected future, however, proportion cirrhosis up 14% morbidity associated 10% year 2030 subsequent increment costs. However, treating from 10 50% result reduction 6 26% 4 20% mortality, respectively. cost per life gained ranges 6078 € for 29-year-old patient 8911 59-year-old patient. Conclusions In increase. Treatment can eradicate infection, patients' survival reduce need liver transplantation, making cost-effective strategy.